A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Clinical trial NCT05026866 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05026866
- Sponsor
- Eli Lilly and Company
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-27
- Primary completion
- 2027-11-01
- Enrollment
- 2996
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.